Biliary tract cancer

Researchers are testing an experimental drug called MRG003 in adults with biliary tract cancer that is EGFR-positive and cannot be removed by surgery or has spread. The trial enrolls people whose cancer worsened after at least one standard treatment. Everyone receives MRG003 by i…

This phase 2 trial is testing whether combining bevacizumab (a blood-vessel growth blocker) with nab-paclitaxel and an oral chemotherapy called S-1 can shrink tumors in people with advanced biliary tract adenocarcinoma that has worsened after initial treatment. About 32 participa…

This study tested a new drug called brigimadlin (BI 907828) in 99 adults with advanced cancers of the bile duct, pancreas, lung, or bladder that have a specific genetic change (MDM2 amplification). Participants took the drug as a tablet once every 3 weeks. The goal was to see if …

This study tested a combination of three drugs—camrelizumab, apatinib, and chemotherapy (gemcitabine plus cisplatin)—in 49 people with advanced biliary tract cancer that could not be removed by surgery. The goal was to see if the combo is safe and how well it shrinks tumors. Resu…

This study tested a new drug called MK-1200 in 13 people with advanced solid tumors, including stomach, esophageal, bile duct, and pancreatic cancers. The goal was to find safe doses and see if the drug could shrink tumors. The study is complete, but results are not yet available…

This study tested a combination of two drugs, lenvatinib and pembrolizumab, in 611 people with advanced cancers like breast, ovarian, stomach, colorectal, brain, bile duct, or pancreatic cancer that had stopped responding to standard treatments. The goal was to see if the combo c…

This Phase 3 trial tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (gemcitabine and cisplatin) helps people with advanced bile duct cancer live longer. The study enrolled 158 Chinese adults with cancer that had spread or could not be removed by…

This study tested two different chemotherapy drug combinations in 92 people with advanced bile duct or gallbladder cancer that could not be removed by surgery. The goal was to see which combination better kept the cancer from growing for at least 6 months. Participants received e…

This early-phase trial tested an experimental drug called BAT8010 in 23 people with advanced or metastatic solid tumors who had no other standard treatment options. The main goals were to check safety, find the best dose, and see if the drug shows any sign of shrinking tumors. Pa…

This study tested a new cancer drug called brigimadlin (BI 907828) in 266 adults with advanced solid tumors that had spread or stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. Brigimadlin is an MDM2 inhibitor tak…

This study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (gemcitabine/cisplatin) helps people with advanced bile duct or gallbladder cancer live longer. Over 1,000 participants received either the combination or chemo plus a placebo. The goal…

This study tested a combination of the targeted drug regorafenib with chemotherapy (mGEMOX) in 66 people with advanced bile duct cancer that could not be removed by surgery. The main goal was to find the safest dose and check for side effects. This is not a cure, but aims to cont…

This phase 2 trial tested the immunotherapy drug nivolumab (Opdivo) in 54 patients with advanced biliary tract cancer that had stopped responding to chemotherapy. The goal was to see if the drug could shrink tumors. While nivolumab is approved for other cancers, it is not yet app…

This study tested a combination of two experimental drugs, AK112 and AK117, with or without chemotherapy, in 154 people with advanced solid tumors. The goal was to see if the combo could shrink tumors and control the disease. The trial has finished, and researchers are now lookin…

This study tested a combination of an immunotherapy drug (nivolumab) and chemotherapy drugs (nanoliposomal-irinotecan, 5-fluorouracil, and leucovorin) in 34 people with advanced biliary tract cancer that had worsened after initial treatment. The goal was to see if the combo could…

This study tested a new combination treatment for people with advanced liver cancer or bile duct cancer. The treatment combines an immunotherapy drug (SHR-1210) with either a targeted therapy (apatinib) or chemotherapy. The goal was to see if the combination is safe and can shrin…

This phase 2 trial tested a combination of two drugs, pembrolizumab (Keytruda) and lenvatinib (Lenvima), in 27 people with advanced biliary tract cancer that had worsened after standard treatment. The goal was to see if the combination could shrink tumors. The study is now comple…

This study tested a combination of three drugs (capecitabine, lenvatinib, and tislelizumab) given after surgery to 65 adults with biliary tract cancer. The goal was to see if this treatment could help keep the cancer from coming back. The results focus on how long patients lived …

This study tracked side effects in 236 people with advanced biliary tract cancer who received IMFINZI (durvalumab) together with standard chemotherapy (gemcitabine and cisplatin). The goal was to see how often adverse reactions happen in everyday medical practice, outside of a co…

This study tested a new way to open the bile duct during an ERCP procedure. Instead of the standard pull-type cut, doctors used a special hooked knife (ASD) designed to cut only the circular muscle layer, potentially causing less damage. Over 1,500 patients were randomly assigned…

This phase 2 trial tested a new chemotherapy combination (Nal-IRI with 5-FU and leucovorin) against a standard treatment (gemcitabine plus cisplatin) in 93 people with advanced biliary tract cancer that could not be removed by surgery. The study aimed to see which approach better…

This study tested a combination of three drugs—chemotherapy (mFOLFOX6), an immunotherapy (atezolizumab), and a targeted therapy (bevacizumab)—in 20 people with advanced bile duct cancer who had already received one prior treatment. The goal was to see if the combination could shr…

This study tested a drug called ZW25 (zanidatamab) in 87 people with advanced or metastatic HER2-amplified biliary tract cancer that had worsened after standard chemotherapy. The goal was to see if the drug could shrink tumors and how long that effect lasted. The trial is now com…

This study tested a new drug called zanidatamab (ZW25) combined with standard chemotherapy in 74 people with advanced HER2-positive cancers of the stomach, bile duct, or colon. The goal was to see if the combination is safe and shrinks tumors. Results will help decide if larger s…

This pilot study tested high dose rate brachytherapy, a type of internal radiation, in 43 patients with cervical, endometrial, esophageal, prostate, or biliary cancer. The goal was to see if the radiation implants could deliver the planned dose accurately. Participants received b…

This early-stage study tests whether a single dose of psilocybin, the active ingredient in magic mushrooms, can reduce depression and anxiety in people with advanced pancreatic, biliary, or other gastrointestinal cancers. The study enrolls 24 adults aged 19-85 with stage IV or in…

This phase 2 trial looked at whether adding acupuncture and acupressure to oral cryotherapy (sucking on ice chips) can reduce nerve pain caused by oxaliplatin chemotherapy in people with gastrointestinal cancers. 78 patients were split into two groups: one got cryotherapy alone, …

This study investigates whether PET-CT scans can accurately measure the radiation dose delivered by radioactive spheres during a liver cancer treatment called radioembolization. Researchers will compare scans taken before and after the procedure in patients with liver tumors. The…

This study followed 159 people with metastatic colorectal, pancreatic, biliary, or esophageal cancers who were starting a new line of therapy. Researchers collected blood samples (tumor markers and liquid biopsies) and patient-reported quality-of-life data to see if these could p…

This study looked at medical records of 729 people in Japan with biliary tract cancer that could not be removed by surgery. Researchers wanted to see if bile duct problems during first treatment affected how long patients could stay on that treatment. The study did not test any n…

This study looks at whether the drug T-DXd works better than standard treatments for people with several types of HER2-positive solid tumors. Researchers will compare data from previous T-DXd trials with real-world medical records of patients who received standard care. The goal …

This study looked at 120 adults with breast, pancreatic, or biliary cancer to see if a new 3D measurement method (TDTP-RECIST) is better than the standard way (RECIST 1.1) for tracking tumor shrinkage before surgery. Researchers compared imaging results with actual tumor tissue r…

This study looked at whether two simple frailty questionnaires (G8 and VES-13) can predict serious side effects from chemotherapy in people 65 and older with gastrointestinal cancers. Researchers followed 72 patients receiving standard chemotherapy and checked their frailty, nutr…

This completed registry study gathered information from 159 people with biliary tract cancers, including gallbladder cancer. The goal was to create a detailed database of patient experiences, treatments, and quality of life to help guide future research. No new drug or treatment …

This study looked at whether two easy-to-use frailty checklists (FRAIL and FiND) can predict severe side effects from chemotherapy in adults aged 65 and older with gastrointestinal cancers. Researchers followed 84 patients who had already had surgery and were receiving standard c…

This study tracked over 700 people in Korea who were already receiving the cancer drug Imfinzi (durvalumab) for lung or biliary tract cancer. The goal was to see how safe and effective the drug is in everyday medical practice, not just in strict clinical trials. Researchers monit…